Akeso Biomedical Appoints Greg W. Lee to Board of Directors

Share Article

Former President of Tyson Foods International to Help Commercialize Food Safety Technology

Greg W. Lee

Greg W. Lee

The company’s novel feed additive technology for controlling Salmonella, Campylobacter, and E. coli in chicken provides a firm foundation to develop products to significantly reduce foodborne illnesses.

Akeso Biomedical, Inc., announced that experienced poultry industry executive Greg W. Lee has joined its board of directors. Akeso Biomedical is a privately held food safety company developing new solutions to reduce Salmonella, Campylobacter, and E. coli in chicken. The announcement of Mr. Lee’s appointment follows the USDA’s recent decision to implement new federal standards to reduce Salmonella and Campylobacter in chicken and turkey products.

Greg Lee joined Tyson Foods in 1980, and rose progressively through the ranks in sales, marketing, operations and general management both domestically and internationally, and became the Chief Operating Officer in 2001, and subsequently the President of Tyson Foods International and Chief Administrative Officer of Tyson Foods until 2007. Since his retirement from Tyson, Greg serves on a number of boards, and is active in assisting companies developing new technologies.

Simon Williams, CEO of Akeso Biomedical, said, “Greg brings global experience as one of the food industry’s top operating executives. His knowledge of the poultry industry as well as other sectors of the food industry will be invaluable to Akeso as we transition to a commercial company.”

“I am delighted to join the Akeso board, and look forward to providing assistance in the development of an exciting new food safety company,” said Greg Lee. “The company’s novel feed additive technology for controlling Salmonella, Campylobacter, and E. coli in chicken provides a firm foundation to develop products to significantly reduce foodborne illnesses.”

About Akeso Biomedical, Inc.

Akeso Biomedical, Inc. is a food safety company focused on developing new solutions for the prevention of foodborne illnesses using a proprietary broad-spectrum iron complex chemistry known as Fe3C. The Company’s product pipeline includes Fe3C feed additives designed to reduce the infection of poultry and other animals by Salmonella, Campylobacter, and E. coli. For more information please send inquiries to contact(at)akesobiomedical(dot)com.

Akeso Biomedical, Inc. is a VIC Technology Venture Development™ portfolio company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bernie Prusaczyk, Chairman of the Board
Visit website

Media

Akeso Biomedical, LLC logo